Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alpine Immune Sciences Inc (ALPN)
NASDAQ:ALPN
RESEARCH TOOLSreports
Alpine Immune Sciences (ALPN) Stock Price & Analysis
446 Followers
ALPN Stock Chart & Stats
Day’s Range$64.97 - $65
52-Week Range― - ―
Previous Close$64.96
Volume4.29M
Average Volume (3M)N/A
Market Cap
$4.46B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$61.50Price Target Upside-5.34% Downside
Rating ConsensusHold
Number of Analyst Covering9
Alpine Immune Sciences News
PremiumCompany Announcements
Alpine Immune Sciences Communicates Key Updates Regularly
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressALPN's presentation of additional data at the World Congress of Nephrology highlights ongoing progress in clinical trials, potentially enhancing the drug's profile.
Drug EfficacyPovetacicept's superior tissue distribution and disease modifying properties, along with its significant reduction of disease parameters in lupus models, indicate a strong therapeutic potential.
Financial OutlookThe analyst's increased price target to $42 for ALPN reflects growing confidence in the drug's market potential and the strategic direction of the company.
Bears Say
Financial ImpactThe previously disclosed option exercise fee of $75 million has been reduced to $10 million, and the remaining pre-option development milestone has been removed.
Partnership Agreement ChangesALPN's revised agreement includes lower residual economics with partner ABBV.
Strategic ShiftsAnalyst interprets the recent disclosure as a strategic deprioritization of acazicolcept.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ALPN FAQ
What was Alpine Immune Sciences Inc’s price range in the past 12 months?
Currently, no data Available
What is Alpine Immune Sciences Inc’s market cap?
Currently, no data Available
When is Alpine Immune Sciences Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Alpine Immune Sciences Inc’s earnings last quarter?
Currently, no data Available
Is Alpine Immune Sciences Inc overvalued?
According to Wall Street analysts Alpine Immune Sciences Inc’s price is currently Overvalued.
Does Alpine Immune Sciences Inc pay dividends?
Alpine Immune Sciences Inc does not currently pay dividends.
What is Alpine Immune Sciences Inc’s EPS estimate?
Alpine Immune Sciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alpine Immune Sciences Inc have?
Currently, no data Available
What happened to Alpine Immune Sciences Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Alpine Immune Sciences Inc?
Among the largest hedge funds holding Alpine Immune Sciences Inc’s share is Woodline Partners LP. It holds Alpine Immune Sciences Inc’s shares valued at 10M.
---
Alpine Immune Sciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$61.50 (-5.34% Downside)
$61.50 (-5.34% Downside)
Blogger Sentiment
Bullish
ALPN Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 5.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 5.4%
Last 30 Days ▼ 5.4%
Company Description
Alpine Immune Sciences Inc
Alpine Immune Sciences, Inc. is a development-stage pharmaceutical company, which engages in the discovering of protein-based immunotherapies therapies targeting the immune synapse to treat cancer, autoimmune, and inflammatory disorders. It offers Immunotherapy, Immune Synapse, vIgD Platform Technology, and TIP Program. The company was founded in 2015 and is headquartered in Seattle, WA.
---
ALPN Stock 12 Month Forecast
Average Price Target
$61.50
▼(-5.34% Downside)
Technical Analysis
Adaptimmune Therapeutics
―
Allogene Therapeutics
―
Aurinia Pharmaceuticals
―
BioCryst
―
Best Analysts Covering ALPN
1 Year
1 Year Success Rate
2/2 ratings generated profit
1 Year Average Return
+85.20%
assigned a buy rating 4 months ago
Copying Matthew Biegler's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +85.20% per trade.
---